Delcath Systems, Inc - On April 25, 2008, Delcath Systems, Inc....

Delcath Systems, Inc - Recent Material Event

Item 8.01 OTHER EVENTS.

On April 25, 2008, Delcath Systems, Inc. (the “Company”) announced that the Institutional Review Board of the University of Maryland Medical Center (“UMMC”) has approved UMMC’s participation in the Phase III study of the Company’s Percutaneous Hepatic Perfusion System for the isolated, high dose delivery of the anti-cancer agent melphalan to treat inoperable metastatic melanoma in the liver. The Phase III study is being led by the National Cancer Institute which previously approved the study’s expansion to a multi-center trial. The Company and UMMC have entered into a clinical research agreement enabling the hospital to immediately begin recruiting and treating patients. H. Richard Alexander, M.D., Professor of Surgery and Associate Chairman for Clinical Research, Surgery at the University of Maryland will serve as Principal Investigator of the study at this new center.

A copy of the Company’s press release announcing the events described above is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a)	Not applicable.
(b)	Not applicable.
(c)	Not applicable.
(d)	Exhibits

No.	Description
99.1	Press release of the Company dated April 25, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.